Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes plc (Nasdaq: ALKS) has announced its participation in two upcoming investor conferences in November 2024.

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Stifel Healthcare Conference on November 18 at 8:35 a.m. ET and the Jefferies London Healthcare Conference on November 19 at 8:00 a.m. ET. Live webcasts will be available on Alkermes' website under the Investors tab and archived for 14 days.

Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.

Argus Session date unavailable

-2.81% session move Open Argus

Details

News Market Reaction – ALKS

The recorded move for ALKS in the trading session of this news was -2.81%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences.

Stifel Healthcare Conference
Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT)

Jefferies London Healthcare Conference
Date/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-two-upcoming-investor-conferences-302301608.html

SOURCE Alkermes plc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Alkermes (ALKS) presenting at the Stifel Healthcare Conference in 2024?

Alkermes (ALKS) is presenting at the Stifel Healthcare Conference on Monday, November 18, 2024, at 8:35 a.m. ET (1:35 p.m. GMT).

What time is Alkermes (ALKS) presenting at the Jefferies London Healthcare Conference?

Alkermes (ALKS) is presenting at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. ET (1:00 p.m. GMT).

How long will Alkermes (ALKS) investor conference webcasts be available?

The webcasts of Alkermes' investor conference presentations will be archived and available for 14 days on the company's website under the Investors tab.

What therapeutic areas does Alkermes (ALKS) focus on?

Alkermes focuses on neuroscience, developing treatments for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and has pipeline candidates for neurological disorders including narcolepsy and idiopathic hypersomnia.